共 50 条
- [1] Autologous stem cell transplantation (ASCT) after conditioning therapy with intermediate dose melphalan, bortezomib,thalidomide, dexamethasone (MVTD) in relapsed multiple myeloma (MM) patients [J]. HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 : 212 - 212
- [2] Autologus stem cell transplantation (ASCT) conditioning therapy intermediate dose Melphalan, Bortezomib, Thalidomide, Dexamethasone (MVRO) in relapsed multiple myeloma (MM) [J]. HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 : 437 - 437
- [3] Bortezomib, melphalan, prednisone, and thalidomide for relapsed multiple myeloma [J]. BLOOD, 2007, 109 (07) : 2767 - 2772
- [4] Bortezomib in combination with low-dose oral melphalan, dexamethasone and thalidomide for relapsed elderly patients with multiple myeloma [J]. JOURNAL OF RESEARCH IN MEDICAL SCIENCES, 2012, 17 (01): : 8 - 14
- [6] Bortezomib in relapsed and refractory multiple myeloma patients.: Experience of a single center [J]. HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 : 151 - 151
- [9] BORTEZOMIB, LOW DOSE INTRAVENOUS MELPHALAN AND DEXAMETHASONE FOR PATIENTS WITH RELAPSED MULTIPLE MYELOMA [J]. HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2008, 93 : 365 - 366